Patents by Inventor Hitto Kaufmann
Hitto Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220064690Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.Type: ApplicationFiled: November 12, 2021Publication date: March 3, 2022Inventors: Lore FLORIN, Hitto KAUFMANN, Angelika HAUSSER, Monilola OLAYIOYE, Michaela STROTBEK
-
Patent number: 9340592Abstract: The invention concerns the field of cell culture technology. The invention describes production host cell lines comprising vector constructs comprising a CERT S132 A expression cassette. Those cell lines have improved growth characteristics and high CERT S132A expression levels. The invention especially concerns two cell lines deposited with the DSMZ under the number DSM ACC2989 (CHO/CERT 2.20) and DSM AC-C2990 (CHO/CERT 2.41). The invention further concerns a method of generating such preferred production host cells and a method of producing proteins using the two cell lines deposited with the DSMZ under the number DSM ACC2989 (CHO/CERT 2.20) and DSM ACC2990 (CHO/CERT 2.41).Type: GrantFiled: May 4, 2010Date of Patent: May 17, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Lore Florin, Eric Becker, Hitto Kaufmann
-
Patent number: 8962312Abstract: The invention concerns the field of cell culture technology. The invention describes production host cell lines comprising vector constructs comprising a DHFR expression cassette. Those cell lines have improved growth characteristics in comparison to DHFR-deficient or DHFR-reduced cell lines such as CHO DG44 and CHO DUKX-B11. The invention especially concerns two cell lines, a representative of each cell line is deposited with the DSMZ under the number DSM ACC2909 (CHOpper® Discovery) and DSM ACC2910 (CHOpper® Standard). The invention further concerns a method of producing proteins using the cells generated by the described method.Type: GrantFiled: July 22, 2009Date of Patent: February 24, 2015Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker, Joey M. Studts
-
Patent number: 8597909Abstract: The present invention refers to the area of cell culture technology and relates to methods for multiplying/cloning cells, preferably cell lines, which are important to the production of biopharmaceuticals. The invention further relates to methods for manufacturing proteins and to the use of cells extracted and multiplied through single cell sorting and to media compositions that enable a multiplication of single cells. Through the use of albumin-producing, preferably HSA-producing, cells as feeder cells for the conditioning of medium or as host cells, the recloning efficiency and thereby the quantity of clones obtained can be significantly increased. A combination of these approaches is also possible. Through the use of albumin-producing, preferably HSA-producing, cells, an increase in the recloning efficiency can be achieved in serum-free and/or insulin-free medium as well, and in different cell types.Type: GrantFiled: September 9, 2009Date of Patent: December 3, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Lore Florin, Rebecca Bischoff, Juergen Fieder, Hitto Kaufmann, Thomas Krieg
-
Patent number: 8563303Abstract: The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. By using IGF particularly in conjunction with HSA in the culture medium after recloning, the recloning efficiency and hence the quantity of clones obtained can be increased significantly.Type: GrantFiled: March 16, 2009Date of Patent: October 22, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Jüergen Fieder, Lore Florin, Hitto Kaufmann, Thomas Krieg, Melanie Briegel
-
Patent number: 8535940Abstract: The invention concerns the field of cell culture technology. It concerns a method of improving cell growth, especially the growth of biopharmaceutical producer host cells. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: GrantFiled: January 22, 2008Date of Patent: September 17, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker
-
Publication number: 20130210074Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: April 9, 2013Publication date: August 15, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore FLORIN, Barbara ENENKEL, Martin FUSSENEGGER, Hitto KAUFMANN, Raffaella SANTORO
-
Publication number: 20130196430Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: June 12, 2012Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
-
Publication number: 20130197196Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: June 12, 2012Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
-
Publication number: 20130177919Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: February 29, 2008Publication date: July 11, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
-
Publication number: 20120258496Abstract: The invention concerns the field of cell culture technology. It specifically concerns a rat hepatoma cell, preferably a H4-II-E rat hepatoma cell, carrying a DNA encoding an antibody or Fc-fusion protein and having low fucosylation activity for adding fucose to glycosidic structures such as biantennary glycans, e.g. N-acetylglucosamine. The invention furthermore concerns a method for producing low fucose glycoproteins especially antibodies or Fc-fusion proteins in rat hepatoma cells, preferably in H4-II-E rat hepatoma cells. It further concerns the identification and generation of new host cell lines which are capable of synthetizing glycoproteins with beneficial properties, improving the therapeutic efficacy and/or serum half-life of the product compared to products from commonly used host cell lines.Type: ApplicationFiled: September 22, 2011Publication date: October 11, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Kristina Ellwanger, Lore Florin, Hitto Kaufmann
-
Publication number: 20120190065Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through introduction of nucleic acids encoding UBF or reducing expression of NoRC proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: May 12, 2010Publication date: July 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore Florin, Barbara Enenkel, Martin Fussenegger, Hitto Kaufmann, Raffaella Santoro
-
Patent number: 8221999Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: GrantFiled: February 29, 2008Date of Patent: July 17, 2012Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
-
Publication number: 20120100553Abstract: The invention concerns the field of cell culture technology. The invention describes production host cell lines comprising vector constructs comprising a CERT S132 A expression cassette. Those cell lines have improved growth characteristics and high CERT S132A expression levels. The invention especially concerns two cell lines deposited with the DSMZ under the number DSM ACC2989 (CHO/CERT 2.20) and DSM AC-C2990 (CHO/CERT 2.41). The invention further concerns a method of generating such preferred production host cells and a method of producing proteins using the two cell lines deposited with the DSMZ under the number DSM ACC2989 (CHO/CERT 2.20) and DSM ACC2990 (CHO/CERT 2.41).Type: ApplicationFiled: May 4, 2010Publication date: April 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore Florin, Eric Becker, Hitto Kaufmann
-
Publication number: 20110281301Abstract: The invention concerns the field of protein production and cell culture technology. It describes a method of producing a heterologous protein of interest in a cell comprising a. Increasing the expression or activity of a secretion enhancing gene, and b. Increasing the expression or activity of an anti-apoptotic gene, and c. Effecting the expression of said protein of interest, whereby the secretion enhancing gene is a gene encoding a protein whose expression or activity is induced during one of the following cellular processes: plasma-cell differentiation, unfolded protein response (UPR), endoplasmic reticulum overload response (EOR).Type: ApplicationFiled: October 6, 2008Publication date: November 17, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto Kaufmann, Eric Becker, Lore Florin, Barbara Enenkel, Kerstin Sautter, Rebecca Bischoff
-
Publication number: 20110262967Abstract: The present invention refers to the area of cell culture technology and relates to methods for multiplying/cloning cells, preferably cell lines, which are important to the production of biopharmaceuticals. The invention further relates to methods for manufacturing proteins and to the use of cells extracted and multiplied through single cell sorting and to media compositions that enable a multiplication of single cells. Through the use of albumin-producing, preferably HSA-producing, cells as feeder cells for the conditioning of medium or as host cells, the recloning efficiency and thereby the quantity of clones obtained can be significantly increased. A combination of these approaches is also possible. Through the use of albumin-producing, preferably HSA-producing, cells, an increase in the recloning efficiency can be achieved in serum-free and/or insulin-free medium as well, and in different cell types.Type: ApplicationFiled: September 9, 2009Publication date: October 27, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Lore Florin, Rebecca Bischoff, Juergen Fieder, Hitto Kaufmann, Thomas Krieg
-
Publication number: 20110230642Abstract: The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. By using IGF particularly in conjunction with HSA in the culture medium after recloning, the recloning efficiency and hence the quantity of clones obtained can be increased significantly.Type: ApplicationFiled: March 16, 2009Publication date: September 22, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Juergen Fieder, Lore Florin, Hitto Kaufmann, Thomas Krieg, Melanie Briegel
-
Publication number: 20110124108Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: May 13, 2010Publication date: May 26, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore FLORIN, Barbara ENENKEL, Martin FUSSENEGGER, Hitto KAUFMANN, Raffaella SANTORO
-
Publication number: 20100086967Abstract: The invention concerns the field of cell culture technology. It concerns a method of improving cell growth, especially the growth of biopharmaceutical producer host cells. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: January 22, 2008Publication date: April 8, 2010Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker
-
Publication number: 20100086947Abstract: Production of biopharmaceuticals from CHO cells requires generation of master-, working- and post-production cell banks of high quality, partly under GMP conditions. An optimal cryopreservation strategy is needed for each new production cell line, particularly with regard to the desire to establish production processes that are completely devoid of serum or even any animal components and to ensure robust thaw performance for reliable production. Here we describe a novel strategy employing flow cytometric (FC) analysis of Annexin V-stained cells for high-throughput characterization of CHO cell banks. Our data show that this method enables evaluation of a cryopreservation procedure just 6 h after thaw.Type: ApplicationFiled: June 25, 2009Publication date: April 8, 2010Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Hitto KAUFMANN, Juergen FIEDER, Ralf OTTO